Fig. 1 · Structure

Documents & Downloads

AMG 208

Cat. No. A10063 CAS 1002304-34-8

c-Met Inhibitor

AMG 208 is a novel c-Met inhibitor that inhibits the ligand-dependent and ligand-independent activation of c-Met, inhibiting its tyrosine kinase activity.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

AMG-208 binds isolated human MET in competitive TR-FRET assays. A kinetic binding study reported a KD of 2.081 nM, with an association rate of 4.3395 × 10^6 M^-1 s^-1 and a dissociation rate of 8.221 × 10^-3 s^-1. These are purified-protein binding measurements; they do not establish a cellular working concentration. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
c-Met 9 nM

Cellular Effect

Cell Line Activity Value Description Reference
PC-3 IC50 46 nM Inhibition of HGF-mediated human c-Met autophosphorylation expressed in human PC3 cells after 1 hr by electrochemiluminescent immunoassay [PMID: 19819693]

In Vitro Studies

MET binding affinity and kinetics measured by TR-FRET probe competition

Biochemical assay · Isolated, biotinylated human MET cytoplasmic domain (residues 956–1390; UniProt P08581). MET concentration 0.2 nM; fluorescent Kinase Tracer 236 concentration 50 nM. [1]

AMG-208 bound MET in equilibrium and kinetic probe-competition assays. The kinetic KD was 2.081 × 10^-9 M. Equilibrium IC50 and KD values were flagged ≈ by the authors, indicating CV>100% or n=1 because one run was not evaluable; the specific reason for this row was not distinguished. These binding endpoints do not establish cellular potency or an effective treatment concentration.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MET binding affinity from kinetic probe competitionKD,kin 2.081 × 10^-9 M[1]
Association of AMG-208 with METkon 4.3395 × 10^6 M^-1 s^-1[1]
Dissociation of AMG-208 from METkoff 8.221 × 10^-3 s^-1[1]
Displacement of fluorescent probe from MET at equilibriumIC50 (probe displacement) ≈7.28855 × 10^-10 M[1]
MET equilibrium binding affinity estimated from probe displacementKD,eq ≈5.0320329721362235 × 10^-10 M[1]

Literature-Reported Treatment Conditions

Treatment concentration
Kinetic assay: four concentrations spanning 2.5–2500 nM (10-fold dilution). Equilibrium assay: 11-point, 3.5-fold dilution spanning either 72.5 pM–20 µM or 7.25 pM–2 µM; the AMG-208-specific range is not identified.
Exposure duration
Equilibrium incubation >1 h. Kinetic acquisition settings: 40 cycles at 10-s intervals for MET.
Method
TR-FRET probe competition at room temperature. High control: probe and kinase without test compound; low/background control: probe and streptavidin-terbium without kinase. Equilibrium curves used a four-parameter fit; kinetic traces used a global Motulsky–Mahan fit.
Vehicle
DMSO; final 1% in equilibrium assays. Kinetic assays used 100 nL of DMSO stock in a nominal 10 µL assay (1% by the stated volumes); control wells received DMSO.
Reported limits
Exact AMG-208 equilibrium concentration range, compound-specific valid replicate count and error estimates are not tabulated. General methods specify at least two independent experiments with two duplicates each. The ≈ flag on equilibrium results overrides any assumption of a precise replicate count.
Methods and source locations

Compound reported in the paper: AMG-208; Compound label in the paper: AMG-208; CAS 1002304-34-8 (Table S4)

Supports biochemical binding of the identity-matched molecule to isolated MET. Does not establish Adooq batch performance, cellular activity, animal efficacy, or formulation equivalence.

Supplementary spreadsheet ja8b08048_si_002.xlsx, Tabelle1, row 7148 (Met / AMG-208); headers row 9 and qualification notes rows 2–7; Supplementary Information ja8b08048_si_001.pdf, pp. S2, S4–S10, Table S1 p. S34, Table S2 p. S35, Table S4 p. S37

MET binding affinity from kinetic probe competition: TR-FRET kinetic probe competition; kinetic affinity derived from koff/kon. The tabulated KD is retained without recomputing it from the separately tabulated rate constants. — Supplementary spreadsheet ja8b08048_si_002.xlsx, Tabelle1, row 7148 (Met / AMG-208); headers row 9 and qualification notes rows 2–7; cells G7148:H7148; Supplementary Information ja8b08048_si_001.pdf, pp. S2, S4–S10, Table S1 p. S34, Table S2 p. S35, Table S4 p. S37

Association of AMG-208 with MET: Kinetic probe competition; global Motulsky–Mahan fit. — Supplementary spreadsheet ja8b08048_si_002.xlsx, Tabelle1, row 7148 (Met / AMG-208); headers row 9 and qualification notes rows 2–7; cells K7148:L7148; Supplementary Information ja8b08048_si_001.pdf, pp. S2, S4–S10, Table S1 p. S34, Table S2 p. S35, Table S4 p. S37

Dissociation of AMG-208 from MET: Kinetic probe competition; global Motulsky–Mahan fit. — Supplementary spreadsheet ja8b08048_si_002.xlsx, Tabelle1, row 7148 (Met / AMG-208); headers row 9 and qualification notes rows 2–7; cells M7148:N7148; Supplementary Information ja8b08048_si_001.pdf, pp. S2, S4–S10, Table S1 p. S34, Table S2 p. S35, Table S4 p. S37

Displacement of fluorescent probe from MET at equilibrium: Equilibrium TR-FRET probe competition; four-parameter dose-response fit. This is not a catalytic kinase-activity IC50. — Supplementary spreadsheet ja8b08048_si_002.xlsx, Tabelle1, row 7148 (Met / AMG-208); headers row 9 and qualification notes rows 2–7; cells C7148:D7148; Supplementary Information ja8b08048_si_001.pdf, pp. S2, S4–S10, Table S1 p. S34, Table S2 p. S35, Table S4 p. S37

MET equilibrium binding affinity estimated from probe displacement: Cheng–Prusoff conversion of equilibrium probe-displacement IC50. The ≈ qualification is retained. — Supplementary spreadsheet ja8b08048_si_002.xlsx, Tabelle1, row 7148 (Met / AMG-208); headers row 9 and qualification notes rows 2–7; cells E7148:F7148; Supplementary Information ja8b08048_si_001.pdf, pp. S2, S4–S10, Table S1 p. S34, Table S2 p. S35, Table S4 p. S37

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1002304-34-8
Applications c-Met Inhibitor
Formula C22H17N5O2
Molecular Weight 383.4
SMILES
COC1=CC2=NC=CC(=C2C=C1)OCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 0.22 mg/mL (0.57 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
1% DMSO+30% polyethylene glycol+1% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Georgi V, Schiele F, Berger BT, et al. Binding Kinetics Survey of the Drugged Kinome. Journal of the American Chemical Society (2018). PMID: 30362749 DOI: 10.1021/jacs.8b08048 Source material

Added to your cart

View Cart Checkout
Loading...